Abstract
Background Progression of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) can lead to worsening congestion requiring diuretic intensification (DI), heart failure (HF)-related hospitalizations (HFH), and death. Tafamidis was the only approved ATTR-CM therapy in the US from 2019 until the 2024 approval of acoramidis, which achieves near-complete (≥90%) TTR stabilization. As head-to-head trials are lacking, real-world comparative effectiveness (CE) data are needed to guide treatment selection.
Objective To evaluate real-world CE of acoramidis versus tafamidis in newly treated patients with ATTR-CM.
Methods Retrospective study using Komodo Healthcare Map® US claims data tokenized to Claritas. Patients newly initiating acoramidis or tafamidis between 12/11/2024 and 04/30/2025 with ≥1 prescription claim (first defined as index date) and ≥6 months of continuous enrollment preindex date were included and followed until disenrollment, death, treatment switch, or study end date (07/31/2025). Outcomes included DI (initiation or dose-equivalent escalation of oral loop diuretics, parenteral loop diuretic use, or addition of thiazide-like diuretic) and a composite of DI, HFH (inpatient admission with a HF-related ICD-10-CM diagnosis code in any position), and mortality. Propensity score weighting balanced baseline characteristics, disease severity, comorbidity burden, and baseline medication use. Time-to-event outcomes were assessed using weighted Cox proportional hazards models.
Results After weighting, acoramidis (n=170) and tafamidis (weighted sample size=448) patients were comparable at baseline (mean age, 78.6 vs 78.7 years; male, 80.0% vs 80.2%) with mean follow-up of 139 and 143 days, respectively. DI cumulative incidence curves separated early and remained divergent, with acoramidis significantly reducing the hazard of DI events by 43% compared with tafamidis (11.8% vs 20.5%; HR, 0.57; 95% CI, 0.35-0.92; P=0.021). Acoramidis also had a significantly lower risk of composite events, with a 34% reduction in hazard compared with tafamidis (17.6% vs 26.4%; HR, 0.66; 95% CI, 0.44-0.99; P=0.046).
Conclusions In this first real-world CE study of newly treated patients, acoramidis had significantly lower risk of DI events and composite events of DI, HFH, and mortality than tafamidis, potentially supporting improved clinical stability with acoramidis initiation. Additional evaluation with longer follow-up, larger cohorts, and/or prospective clinical outcomes is warranted.
Competing Interest Statement
Dr Wright has received research funding from BridgeBio Pharma, Inc. and Cytokinetics; speaking fees from Alnylam Pharmaceuticals, American Heart Association, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, BridgeBio Pharma, Inc., Lexicon Pharmaceuticals, Lilly, and Novartis; consultancy fees from Alnylam Pharmaceuticals, American College of Cardiology, American Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, BridgeBio Pharma, Inc., Cytokinetics, MyoKardia, Novartis, and Providence Health; and advisory board fees from Alnylam Pharmaceuticals, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, BridgeBio Pharma, Inc., Cytokinetics, and Novartis. Dr Martyn has received research funding from AstraZeneca, Edwards Lifesciences, and FIRE1; consultancy fees from Acorai, AstraZeneca, Bayer, BridgeBio Pharma, Inc., Dyania Health, Ensho Health, FIRE1, Novo Nordisk, and Pfizer; and equity from Apricity Robotics and Kilele Health. Ms. Keshishian, Dr Nagelhout, and Dr Zeldow are employees of Genesis Research Group, which received financial compensation from BridgeBio Pharma, Inc., for preparing the research reported in the manuscript. Ms Udall is an employee and stockholder of BridgeBio Pharma, Inc., and stockholder of Pfizer, Inc. Dr Lanfear has received research funding from Akros Pharma Inc. (Shionogi), BridgeBio Pharma, Inc., Illumina, Kardigan, and Pfizer; and consultancy fees from AstraZeneca, Bayer, Berlin Heals, Cytokinetics, Illumina, Impulse Dynamics, and RyCarma Therapeutics. Dr Judge has received consultancy fees from Alexion, Alnylam Pharmaceuticals, Attralus, Bayer, BridgeBio Pharma, Inc., Lexeo Therapeutics, Novo Nordisk, and Rocket Pharmaceuticals
Funding Statement
The study was funded by BridgeBio Pharma, Inc. (San Francisco, CA, USA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Komodo database complies with the Health Insurance Portability and Accountability Act. Given the deidentified nature of the data, patient consent and institutional review board approval were not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The title was revised to provide improved clarity.
Data Availability
Qualified academic investigators may submit requests for access to data via MedInfo{at}BridgeBio.com. Requests for access to study data will be evaluated by BridgeBio Pharma, Inc. and access will be provided contingent upon the approval of a research/study proposal and the execution of a data sharing agreement. BridgeBio Pharma will consider requests for access to participant-level data if participant privacy is assured through methods such as data deidentification, pseudonymization, or anonymization (as required by applicable law), and if such disclosures were included in the relevant studys informed consent form or study protocol.
